pimagedine has been researched along with Classic Galactosemia in 5 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the relationship between early retinal capillary cell apoptosis and late histologic lesions of diabetic retinopathy and to compare the effects of aminoguanidine (AMG) on the retinopathies caused by diabetes and galactose feeding." | 3.70 | Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. ( Kern, TS; Kowluru, RA; Lorenzi, M; Mizutani, M; Nagaraj, RH; Podesta, F; Romeo, G; Tang, J, 2000) |
| "To study the effects of an aldose reductase inhibitor (ARI-509, Wyeth-Ayerst, Princeton, NJ) and aminoguanidine (AMG), agents that have been reported to prevent or delay diabetic retinopathy, on retinal vascular abnormalities and the immunocytochemical expression in the retina of vascular endothelial growth factor (VEGF) in rats maintained for up to 2 years on a 50% galactose diet." | 3.69 | An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. ( Amin, R; Frank, RN; Hohman, TC; Kennedy, A, 1997) |
| "Two months of diabetes or experimental galactosemia in rats resulted in elevation of retinal oxidative stress (increase in thiobarbituric acid reactive substances, TBARS, and decrease in glutathione, GSH), NO, and PKC activity." | 1.31 | Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. ( Engerman, RL; Kern, TS; Kowluru, RA, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frank, RN | 1 |
| Amin, R | 1 |
| Kennedy, A | 1 |
| Hohman, TC | 1 |
| Engerman, RL | 2 |
| Kern, TS | 4 |
| Tang, J | 1 |
| Mizutani, M | 1 |
| Kowluru, RA | 2 |
| Nagaraj, RH | 1 |
| Romeo, G | 1 |
| Podesta, F | 1 |
| Lorenzi, M | 1 |
| Berkowitz, BA | 1 |
| Ito, Y | 1 |
| McDonald, C | 1 |
| Hawkins, R | 1 |
5 other studies available for pimagedine and Classic Galactosemia
| Article | Year |
|---|---|
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetic Retinopathy; Endothelial Growth Factors; Enzyme Inhi | 1997 |
Retinopathy and tissue hexose in drug-treated animals.
Topics: Aldehyde Reductase; Animals; Diabetic Retinopathy; Endothelial Growth Factors; Enzyme Inhibitors; Ga | 1998 |
Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia.
Topics: Animals; Apoptosis; Capillaries; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Retinopath | 2000 |
Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet; Galactosemias; Glutathione; Gu | 2000 |
Correction of early subnormal superior hemiretinal DeltaPO(2) predicts therapeutic efficacy in experimental diabetic retinopathy.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; E | 2001 |